Answers are grounded in this paper and cite their sources.
Conventional subcutaneous insulin therapy faces limitations in patient adherence and carries a persistent risk of hypoglycemia, primarily due to the challenges of achieving precise dosing. To address this, glucose-responsive insulin delivery systems have been developed to autonomously adjust insulin release in direct response to real-time fluctuations in blood glucose levels. This approach offers a promising pathway toward achieving more physiological glycemic control. This review systematically summarizes recent advances in the design of such intelligent systems, with a focus on two fundamentally interconnected components: the ongoing evolution of glucose-sensing mechanisms, which encompass enzymatic, non-enzymatic, and transporter-mediated strategies, and the parallel development of advanced carrier materials, including metal-organic frameworks, smart polymers, and bio-derived materials. In addition to outlining these technological developments, this work provides a balanced analysis of the operational principles, relative merits, and key translational challenges inherent in current system designs, with particular attention to long-term biocompatibility, stability, and safety. By presenting a coherent synthesis of the field's current landscape and its potential future directions, this review aims to inform and support the rational development of next-generation glucose-responsive insulin therapies with stronger prospects for clinical translation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: